Corteva CTVA
Basic Materials · Agricultural Inputs · Synthos Deep Dive · 2026-07-03
The Overview
Corteva sells the two things farmers buy every season: seeds (genetically engineered corn and soybean seed with built-in traits) and crop protection (weed-killers, bug-killers, fungicides). It is one of the biggest names in the world at both. The business is steady and financially healthy — it actually holds more cash than debt — but it grows slowly, because there are only so many acres of farmland and only so much a farmer will spend in a soft year.
The catch: the stock is not cheap. You pay about 23 dollars for every dollar of next year's expected profit, which is a full price for a company whose sales barely grow. The share price has also run straight up to its highest level in a year, and a momentum gauge (RSI) is flashing "very overbought" — historically not a great moment to chase.
Our verdict is Watch — a good company, fairly-to-fully priced, worth owning on a pullback but not an obvious buy today.
Here's what our three scores mean in everyday terms:
- Downside Risk 4/10 (fairly low). The balance sheet is strong and the stock is not very jumpy, so a permanent loss is less likely — but it is priced high and tied to the farm economy, which goes in cycles.
- Growth Quality 5/10 (middle). It grows profits, but mostly through cost-cutting and share buybacks, not by selling a lot more — and its returns on the money it invests are only okay.
- Exponential Potential 2/10 (low). This is a mature, slow-growth business. Do not expect it to multiply your money quickly.
The one big worry: farming is cyclical. A bad stretch of low crop prices and tight farmer budgets hits both of Corteva's businesses — seed pricing and pesticide volumes — at the same time.
A 2026 wildcard: Corteva plans to split into two separate companies in the fourth quarter of 2026 — "Vylor" (the seeds/genetics business) and "New Corteva" (crop protection). Splits like this sometimes unlock value; they also add execution risk and one-time costs.
Putting a number on it: our fair-value estimate is $92 against a current price of $83.90 — real upside if our numbers are right.
Our summary metrics
Net-cash balance sheet & beta 0.57 anchor it — but RSI 88.8 at a 52-week high and farm-cycle exposure.
~12% forward EPS CAGR is cost/buyback-led on only ~2.5% revenue growth; ROE ~4.7%, mid-single-digit ROIC.
Mature ag-inputs compounder, revenue growth decelerating to low-single-digits; the 4Q26 spin is re-rating, not exponential compounding.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Mature ag-inputs compounder, revenue growth decelerating to low-single-digits; the 4Q26 spin is re-rating, not exponential compounding.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $90.88 (high $96 / low $86; 23 Buy · 12 Hold · 2 Sell) — context, not our anchor |
| Valuation | 50× trailing GAAP EPS · ~23× FY26E · ~21× FY27E · ~16× FY29E operating EPS · EV/S 3.3× · EV/EBITDA 18.6× |
| Technicals | Uptrend but stretched — $85.80 at the 52-wk high, RSI 88.8 (very overbought), above 50/200-DMA, +14% 12-mo (SPY +21%) |
| Conviction | None — 0 expert voices, 0 traceable claims in the Synthos KB; call rests on quant + fundamentals |
| Position sizing | Watch / small only — a 1–2% cyclical-diversifier at most, and not at an 88 RSI |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for CTVA — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $83.90, 2% above the 50-day average ($83), 9% above the 200-day average ($77) — an uptrend. 7% below the 52-week high of $91, 38% above the 52-week low of $61.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $83.90 is currently inside the band (band $73–$84).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 60.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently above its signal line by 0.86, positive momentum.
Relative performance vs S&P 500 & its sector (XLB (sector)), set to 100 a year ago
Solid = CTVA · dashed = S&P 500 · dotted = XLB (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Corteva, Inc. (NYSE: CTVA) is a pure-play agricultural-inputs company spun out of DowDuPont in 2019 and headquartered in Indianapolis. It operates two segments:
- Seed — advanced germplasm and trait technologies (corn, soybean, and other row crops) that improve yield and confer resistance to weather, disease, insects, and herbicides; plus digital agronomy tools.
- Crop Protection — herbicides, insecticides, fungicides, nitrogen stabilizers, and biologicals that protect and enhance crop health.
Fiscal year ends December 31. FY2025 revenue was $17.40B (+2.9% on FY24's $16.91B).
Revenue mix (FY2025, from filings):
- By segment: Seed $9.90B (57%) · Crop Protection $7.50B (43%). Within Crop Protection: Herbicides $3.73B, Insecticides $1.67B, Fungicides $1.14B, Biologicals $0.52B, Other $0.45B.
- By geography: United States $8.27B (48%) · Latin America $3.93B (led by Brazil $2.90B) · EMEA $3.11B · Asia Pacific $1.34B · Canada $0.76B. Latin America (mostly Brazil) is the swing region and the source of the Crop-Protection pricing pressure management has been flagging.
The defining 2026 event: Corteva is on track to separate into two independent public companies in 4Q 2026 — Vylor (the advanced seed & genetics business) and New Corteva (crop protection). Per the 1Q26 release, Form 10 has been filed, executive teams named (Luke Kissam to lead New Corteva), and an Investor Day is set for 2026-09-15. This is the dominant swing factor for the shares this year (§9, §10).
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of Corteva in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0, and the top list is empty. That is stated plainly here because honesty comes first: we will not manufacture conviction we do not have.
Consequently this verdict is fundamentals- and quant-driven, not conviction-driven. Every number below is sourced from FMP financials/estimates or management's own SEC filing (labeled as such). Where the Street has a view, we show it as context — the sell-side is a "Buy" consensus (23 Buy / 12 Hold / 2 Sell) with a $90.88 target — but the sell-side is not a Synthos expert panel and is not weighted as conviction.
If and when a net-bullish or cautionary voice enters the KB with a traceable claim_id, this section will be rewritten to reconcile to it. Today it does not exist, and the note stands empty by design.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 4 · Low-Moderate | Net-cash balance sheet (net debt −$1.94B, net-debt/EBITDA effectively <0), beta 0.57, defensive staple demand, and near-zero drawdown anchor it. But 50× trailing GAAP / 23× forward leaves little cushion, RSI 88.8 signals a stretched entry, and farm-income cyclicality is a real structural flag. |
| Growth Quality | 5 · Average | ~12% forward EPS CAGR looks fine until you see it rests on only ~2.5% revenue CAGR plus cost programs and buybacks. ROE 4.7%, ROIC ~6.4%, ROCE 9.4% — mid-single-digit returns on capital. Real moat in seed genetics, but this is a mature compounder, not a quality standout. |
| Exponential Potential | 2 · Low | Revenue growth decelerating (+5.3% FY26E → +3.4% FY27E → +2.8% FY28E), a $57B mature category leader, TAM effectively fixed by global crop acreage. The 4Q26 spin is a re-rating catalyst, not exponential compounding. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities; the cases bound the range and the scores above summarize them. Because operating (non-GAAP) EPS is the metric analysts and management guide to — and GAAP is distorted by amortization and separation charges — we anchor the cases on operating EPS and cross-check on EV/EBITDA.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Spin unlocks a sum-of-the-parts re-rating; Brazil crop-protection pricing stabilizes; cost/productivity programs beat. FY27E operating EPS ~$4.35 (top of range) at a post-spin ~25×. | ~$108 (+26%) |
| Base (our anchor) | Estimates roughly hit — FY27E operating EPS ~$4.14; a low-growth but net-cash, moaty ag leader earns ~22×. | ~$92 (+7%) |
| Bear | Ag down-cycle: farm income falls, seed price/mix softens, Crop-Protection price erosion in LatAm/APAC persists; spin costs/dis-synergies bite. FY27E operating EPS ~$3.70 at a de-rated ~19×. | ~$70 (−18%) |
Synthos fair value = the base case, ~$92 (+7%), with the full $70–$108 span as the honest range. This anchor sits essentially on top of the Street's $90.88 consensus — an unusual case where our fundamentals-only model and the sell-side agree the stock is close to fair value. Modest upside, real (if moderate) downside, and no expert edge to lean on = Watch, not Buy. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). CTVA is neither an exponential nor a high-return compounder — it is a mature, cyclical category leader:
- Forward growth: revenue CAGR FY26→FY29E ~2.5% ($18.3B → $19.7B); operating EPS CAGR ~12% ($3.74 → $5.29) — but the EPS growth is manufactured from margin/cost programs and buybacks, not unit demand.
- Acceleration (the 2nd derivative) is negative: revenue growth +5.3% (FY26E) → +3.4% (FY27E) → +2.8% (FY28E). This is a decelerating low-single-digit grower — the opposite of an exponential.
- Room to run: the TAM is effectively capped by global crop acreage and farmer budgets. A $57B ag-inputs leader does not multiply; it grinds out low-single-digit volume + price/mix + trait royalties.
- The one real catalyst is structural, not compounding: the 4Q26 split into Vylor + New Corteva could unlock a sum-of-the-parts re-rating (two focused stories vs one conglomerate discount). That is a one-time value event, not a change in the growth trajectory. Per our flagship philosophy we pick forward next-exponentials over trailing compounders — CTVA is squarely a mature compounder and scores accordingly.
Exponential Potential: Low (2/10). Own CTVA, if at all, for defensive cyclical exposure and the spin optionality — not for growth. This honest framing is why it does not belong in a growth or Degen sleeve.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $17.40B, +2.9% (FY24 $16.91B, −1.8% on FY23 $17.23B). Essentially flat-to-low-single-digit at scale; the business is mature and seasonally lumpy.
- Seasonality (why the quarters swing wildly): Northern-Hemisphere planting concentrates sales in Q1–Q2. Q2'25 revenue $6.46B vs Q3'25 $2.62B and Q4'25 $3.91B; Q4'25 posted a GAAP loss (−$0.82 EPS) on seasonal cost timing. Q1'26 came in strong: revenue $4.91B (+11% YoY), operating EPS $1.50 (+33%). Do not annualize any single quarter.
- Margins: gross 46.8% TTM, EBITDA margin 17.6% TTM, operating ~16.3%, net 6.5% TTM. Segment operating-EBITDA margins are expanding (Seed +310bps, Crop Protection +100bps YoY in Q1'26) on productivity programs — the real profit story.
- Earnings: FY25 GAAP net income $1.09B, GAAP EPS $1.61 (depressed by ~$1.2B D&A and one-offs). Operating/non-GAAP EPS is materially higher and is what the Street and management guide to (FY26 guide $3.45–$3.70).
- Cash flow: FY25 operating CF $3.41B, capex −$0.59B, FCF $2.82B (FCF yield ~3.6%, up sharply from $1.55B FY24 on working-capital normalization). Healthy cash conversion.
- Balance sheet: total debt $2.58B against $4.52B cash → net cash of ~$1.94B. Net-debt/EBITDA is effectively negative; interest coverage 16×. A genuine fortress-lite balance sheet — the strongest single pillar of the low-ish risk score.
6. Valuation — priced in or room?
On trailing GAAP the stock looks eye-watering (50× EPS) but that GAAP number is distorted by heavy amortization and separation charges. The fair lens is operating EPS and EV/EBITDA:
- Forward operating P/E: ~23× FY26E ($3.74) → ~21× FY27E ($4.14) → ~19× FY28E ($4.62) → ~16× FY29E ($5.29). The multiple compresses as cost programs and buybacks lift EPS — but on only ~2.5% revenue growth, that EPS growth is not high-quality.
- EV/EBITDA 18.6× TTM, EV/Sales 3.3× — full for a low-growth ag-inputs name (peers in materials trade high-single to low-teens EV/EBITDA).
- PEG: forward PEG ~1.8× on the ~12% EPS CAGR — not cheap, not egregious.
- FMP letter rating B+ (overall score 3/5), dragged by a P/E sub-score of 1 and P/B of 2 — i.e. the model also flags valuation as the weak link.
- Street targets (context): consensus $90.88, high $96, low $86 — a tight band implying the sell-side sees ~+6% and limited dispersion. Our base FV of ~$92 lands on top of it.
Read: fairly-to-fully valued. There is a credible sum-of-the-parts case that the spin unlocks a re-rating (the bull), but you are not being paid to wait — this is a quality-at-full-price situation with no expert edge, hence Watch.
7. Technicals (from the tech block)
- Trend: up. $85.80 sits above the 50-DMA ($79.75) and 200-DMA ($73.21), and the 50 is above the 200 (golden-cross posture). MACD +1.48 (positive).
- Location: the stock is at its 52-week high ($85.80; 0.0% off high), +40.7% off the 52-week low ($61.00) — a leadership move with essentially zero drawdown from peak.
- Momentum — the caution flag: RSI(14) is 88.8, deeply into overbought (>70) territory. This is the single loudest technical signal: the move is extended and a mean-reversion pullback is statistically likely near-term. Not a chase-here setup.
- Relative strength: +14.2% 12-mo vs SPY +20.6% and QQQ +30.3% — CTVA has lagged the broad market over a year despite a strong recent 6-mo run (+27.4%). This is a recent momentum burst, not persistent leadership.
- Read: technicals say wait for a pullback. An entry toward the rising 50-DMA (~$80) or the 200-DMA (~$73) would be materially lower-risk than buying at an 88 RSI at the high.
8. Moat & competitive position
Corteva's moat is real but narrower than a pharma or software franchise: (1) a germplasm and trait library (proprietary corn/soybean genetics and licensed traits) with high switching costs and multi-year breeding lead times; (2) scale and distribution across every major ag geography; (3) regulatory/registration barriers on crop-protection molecules; and (4) a royalty stream on trait licensing. The offsets: seed and crop-protection are cyclical and price-competitive (note the −2% Crop-Protection price in LatAm/APAC), and off-patent generic crop-chemistry erodes pricing over time.
Peer set (FMP-provided, market cap). Note FMP's peer list for CTVA is poorly matched — it returns mining/materials and aggregates names (gold miners, cement) that are not ag-input competitors: Nutrien $31B (the one true ag-fertilizer peer), Air Products $70B, Nucor $50B, Vale $64B, Martin Marietta $36B, Vulcan $39B, Franco-Nevada $42B, Wheaton $53B, Gold Fields $32B, AngloGold $43B. The real competitive frame (not in the FMP list) is Bayer Crop Science, BASF Agricultural Solutions, Syngenta/ChemChina, and FMC Corp. Treat the FMP peer table as sector-bucket noise, not a comp set.
9. Management, capital allocation & guidance
- Capital allocation: disciplined and shareholder-friendly — FY25 returned ~$1.07B via buybacks and ~$0.48B in dividends (yield ~0.8%, payout ~41%), funded comfortably by $2.8B FCF while holding net cash. Management guided ~$500M of buybacks in 1H26. Capex is light (~$0.6B/yr, ~3% of revenue).
- Insider activity: the sampled window shows routine director equity awards and tax-withholding (F-InKind) transactions around $81, plus a Form 3 for the incoming Crop Protection CEO — normal governance mechanics, no cluster of alarming discretionary selling.
- Management's own guidance — self-interested words, half-weighted (source: SEC 8-K / EX-99.1, 1Q26 earnings release, 2026-05-05): Management reaffirmed full-year 2026 guidance: Operating EBITDA $4.0–$4.2B and Operating EPS $3.45–$3.70. They characterize ag fundamentals as "mixed" but demand as "resilient," with tightening global supply-demand as reduced Chinese export availability helps pricing. Crucially, they confirmed the separation is on track for 4Q 2026 (Vylor = seed/genetics; New Corteva = crop protection), with ~$350M one-time separation costs, ~$100M net dis-synergies (trending favorably), a ~$1.5B discretionary pension contribution before 7/31/26, and an Investor Day on 2026-09-15. This is management's own book — treat the guide as a floor-ish target from an interested party, not independent truth, but it is real, dated, and specific (not fabricated).
10. Catalysts & what to watch
- Next earnings: 2026-07-30 (Q2'26; Street EPS $2.22, revenue ~$6.57B). Q2 is a seasonally huge quarter — watch Seed price/mix and Crop-Protection LatAm pricing (the −2% headwind).
- The separation (dominant catalyst): 4Q 2026. Form 10 effectiveness, final capital structures, credit-agency responses, and the 2026-09-15 Investor Day where the sum-of-the-parts math gets laid out. A clean split into two focused, investment-grade companies is the core bull path.
- Ag cycle: grain/oilseed prices, farm income, and Brazil demand — the exogenous drivers of both segments.
- Cost/productivity execution: continued segment-EBITDA margin expansion (Seed +310bps, CP +100bps in Q1'26) is the earnings engine given flat revenue.
Thesis tripwires (what would change the call): the separation slipping or being scrapped; two quarters of Crop-Protection volume decline; seed price/mix turning negative; or FY26 guidance being cut below the $3.45 operating-EPS floor.
11. Key risks
- Ag-cycle cyclicality (structural): a downturn in crop prices and farm income compresses seed pricing and crop-protection volumes simultaneously — the single biggest risk.
- Valuation / stretched entry: ~23× forward on ~2.5% revenue growth, at a 52-week high with RSI 88.8 — little cushion if a quarter disappoints.
- Separation execution: dis-synergies, ~$350M one-time costs, stranded costs, and the risk that two smaller companies do not re-rate as hoped.
- Crop-Protection price erosion: ongoing generic competition, especially in Latin America and APAC (−2% price in Q1'26).
- FX / emerging-market exposure: large Brazil/LatAm and EMEA revenue base introduces currency and country risk.
- No expert coverage: Synthos has zero KB conviction here — the call leans entirely on quant/fundamentals, which is a lower-confidence footing than a conviction name.
12. Verdict, position sizing & monitoring
Watch. Corteva is a well-run, net-cash, moaty global ag-inputs leader — but it is a low-growth, cyclical business trading at a full ~23× forward operating earnings, at a 52-week high, with RSI near 89 and no expert edge in the Synthos KB. Our fundamentals-only fair value (~$92) sits right on the Street's $90.88 consensus: modest upside, real downside, no margin of safety. The 4Q26 spin is a genuine value-unlock catalyst worth watching, but it is a re-rating event, not a growth inflection, and it does not justify chasing the stock here.
- Sizing: if owned at all, a small (~1–2%) cyclical/defensive diversifier, and not initiated at an 88 RSI. Prefer to wait for a pullback toward the 50-DMA (~$80) or the 200-DMA (~$73), or for clarity on the separation terms at the 9/15 Investor Day.
- Monitoring: re-underwrite on the tripwires in §10; formal re-score at the 7/30 print and again around the spin. Upgrade to Buy — Tactical if it pulls back to the low-$70s (bear-case floor) with the spin on track, or if a credible SOTP re-rating case emerges from the Investor Day.
- Single biggest risk: an ag-cycle downturn hitting seed pricing and crop-protection volumes at once.
This verdict is logged as a tracked Synthos call as of 2026-07-03 at $85.80.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — there is no expert coverage of CTVA in the Synthos knowledge base. This note is explicitly fundamentals- and quant-driven; no conviction is claimed or fabricated (claim-ID reconciliation makes fabrication structurally impossible).
- Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from the 2026-05-05 SEC 8-K (EX-99.1). Forward figures are analyst consensus (FMP) or management guidance, each labeled as an estimate.
- Management caveat: the FY26 guidance in §9 is management's own, self-interested words, half-weighted by design.
- Peer-set caveat: FMP's peer list is mis-bucketed (mining/materials names); the real ag-input comps (Bayer, BASF, Syngenta, FMC, Nutrien) are noted in §8.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").